SynthesisBMC gastroenterology2025
Effects of Helicobacter pylori infection on gastric cancer, obesity and esophageal diseases: a systematic review and meta-analysis.
Synthesis in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAt present, the specific mechanism by which Helicobacter pylori (H. pylori) infection leads to gastric cancer (GC) is not clear. This study aims to systematically evaluate the correlation between H. pylori infection and the risk of GC, obesity and esophageal diseases by collecting and analyzing existing relevant studies, update the existing evidence-based medical evidence, and provide evidence to inform the etiology-based prevention and treatment of GC, obesity and esophageal diseases and further clinical research.
methodsLiterature search of the PubMed, Embase, Web of Science, Cochrane Library, ClinicalTrials.gov, CNKI, and Wanfang databases (as of June 27, 2023) was performed. Population-based studies (sample size n > 100) that reported the associations of H. pylori infection with GC, obesity, and esophageal disease and used objective methods to detect H. pylori infection were selected. Data such as effect sizes and 95% CI were extracted for analysis, and interstudy heterogeneity was analyzed on the basis of study location and certain other characteristics.
resultsForty relevant studies were included, including 15, 4 and 21 studies on GC, obesity and esophageal diseases respectively. The results revealed that H. pylori infection was positively correlated with the risk of GC [OR (95% CI) = 2.68 (1.85 ~ 3.89) ; P < 0.0001], and was negatively associated with the risk of obesity [OR (95% CI) = 0.65 (0.43 ~ 0.98); P = 0.0380] and gastroesophageal reflux disease (GERD) [OR (95% CI) = 0.54 (0.43 ~ 0.68); P < 0.0001], and had no significant association with the risk of esophageal cancer (EC) [OR (95% CI) = 0.90 (0.47 ~ 1.73); P = 0.7454]. There was considerable heterogeneity among studies for some diseases, but sensitivity analysis proved that the results were stable and reliable, and no significant publication bias was found.
conclusionH. pylori infection increases the risk of GC, H. pylori eradication is highly important for reducing the risk of GC. H. pylori infection was not associated with reduced risk of obesity and GERD, but the related evidence is limited and the mechanism is not clear. Based on the available evidence, decision-making for eradication treatment should follow the principle of individualization, taking into account the patient’s disease risk, strain characteristics, demographic factors, and the cost-effectiveness of treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.